Healthcare provider profile · identity verified

Benjamin J Hicks, MD

Allopathic & Osteopathic Physicians|Family Medicine · OSCEOLA, IA · NPI 1124353099

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Benjamin J Hicks, MD received $35.33 in general payments during 2025 across 2 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 53.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$35.33

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$18.85	53.4%	1	2025
Abbott Laboratories	Unresolved — no canonical attribution shown	$16.48	46.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$18.85	1
Food and Beverage	$16.48	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$18.85	1	2025
Source payment records 2025-10-01 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source
FREESTYLE LIBRE 3 Normalized: freestyle libre 3	Device	Abbott Laboratories	$16.48	1	2025
Source payment records 2025-12-28 · Abbott Laboratories · $16.48 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	191	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	191	37

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	709	191
Amlodipine Besylate	Amlodipine Besylate	489	126
Lisinopril	Lisinopril	436	110
Levothyroxine Sodium	Levothyroxine Sodium	426	90
Losartan Potassium	Losartan Potassium	333	85
Metoprolol Succinate	Metoprolol Succinate	318	78
Omeprazole	Omeprazole	318	94
Ozempic	Semaglutide	306	50
Furosemide	Furosemide	296	73
Hydrochlorothiazide	Hydrochlorothiazide	288	80
Sertraline Hcl	Sertraline Hcl	262	58
Potassium Chloride	Potassium Chloride	250	75
Pantoprazole Sodium	Pantoprazole Sodium	199	53
Jardiance	Empagliflozin	191	37
Tamsulosin Hcl	Tamsulosin Hcl	176	45
Gabapentin	Gabapentin	173	49
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	169	35
Metformin Hcl	Metformin Hcl	164	40
Fluticasone Propionate	Fluticasone Propionate	148	56
Trazodone Hcl	Trazodone Hcl	145	35
Simvastatin	Simvastatin	144	43
Albuterol Sulfate Hfa	Albuterol Sulfate	131	38
Alendronate Sodium	Alendronate Sodium	128	36
Metoprolol Tartrate	Metoprolol Tartrate	125	34
Tramadol Hcl	Tramadol Hcl	124	36
Venlafaxine Hcl Er	Venlafaxine Hcl	124	27
Rosuvastatin Calcium	Rosuvastatin Calcium	121	33
Warfarin Sodium	Warfarin Sodium	114	20
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	109	17
Allopurinol	Allopurinol	93	20
Glipizide	Glipizide	87	23
Mounjaro	Tirzepatide	85	22
Finasteride	Finasteride	83	16
Eliquis	Apixaban	82	23
Metformin Hcl Er	Metformin Hcl	79	25
Spironolactone	Spironolactone	72	21
Prednisone	Prednisone	70	53
Duloxetine Hcl	Duloxetine Hcl	67	17
Pregabalin	Pregabalin	67	11
Ezetimibe	Ezetimibe	65	21
Mirtazapine	Mirtazapine	64	suppressed
Montelukast Sodium	Montelukast Sodium	64	19
Trulicity	Dulaglutide	62	11
Escitalopram Oxalate	Escitalopram Oxalate	60	15
Clopidogrel	Clopidogrel Bisulfate	59	14
Meloxicam	Meloxicam	59	25
Diclofenac Sodium	Diclofenac Sodium	56	26
Glipizide Er	Glipizide	55	22
Bupropion Xl	Bupropion Hcl	54	15
Atenolol	Atenolol	52	14
Clonazepam	Clonazepam	51	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	51	33
Xarelto	Rivaroxaban	51	suppressed
Donepezil Hcl	Donepezil Hcl	50	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	50	suppressed
Januvia	Sitagliptin Phosphate	50	suppressed
Ropinirole Hcl	Ropinirole Hcl	48	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	47	15
Pravastatin Sodium	Pravastatin Sodium	46	suppressed
Benazepril Hcl	Benazepril Hcl	45	13
Famotidine	Famotidine	45	suppressed
Carvedilol	Carvedilol	42	suppressed
Bumetanide	Bumetanide	41	suppressed
Memantine Hcl	Memantine Hcl	41	suppressed
Citalopram Hbr	Citalopram Hydrobromide	39	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	39	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	38	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	37	12
Rybelsus	Semaglutide	37	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	17
Myrbetriq	Mirabegron	35	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	35	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	35	21
Zolpidem Tartrate	Zolpidem Tartrate	35	suppressed
Fentanyl	Fentanyl	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	32	21
Fluconazole	Fluconazole	32	20
Tresiba Flextouch U-100	Insulin Degludec	32	suppressed
Buspirone Hcl	Buspirone Hcl	31	suppressed
Spiriva Handihaler	Tiotropium Bromide	31	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Baclofen	Baclofen	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Ventolin Hfa	Albuterol Sulfate	28	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Celecoxib	Celecoxib	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Risperidone	Risperidone	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Azithromycin	Azithromycin	21	20
Glimepiride	Glimepiride	21	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Aripiprazole	Aripiprazole	20	suppressed
Nystatin	Nystatin	20	13
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	20	suppressed
Propranolol Hcl Er	Propranolol Hcl	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Spiriva Respimat	Tiotropium Bromide	20	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Cephalexin	Cephalexin	18	15
Lorazepam	Lorazepam	18	11
Naproxen	Naproxen	18	suppressed
Ramipril	Ramipril	18	suppressed
Cefdinir	Cefdinir	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Eszopiclone	Eszopiclone	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	17	suppressed
Ondansetron Odt	Ondansetron	17	13
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Labetalol Hcl	Labetalol Hcl	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Digoxin	Digoxin	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	13	suppressed
Rivastigmine	Rivastigmine Tartrate	13	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Diazepam	Diazepam	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Lithium Carbonate	Lithium Carbonate	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Temazepam	Temazepam	12	suppressed
Tiotropium Bromide	Tiotropium Bromide	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Cholestyramine	Cholestyramine (With Sugar)	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Valproic Acid	Valproic Acid	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$35.33 · 2 records	Boehringer Ingelheim Pharmaceuticals, Inc.	FREESTYLE LIBRE 3, JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error